 |
| Sent to you from Drugs.com You received this email because you requested to receive drug alerts. Change your notification settings or unsubscribe here. |
Sent to subscribers of: dronedarone systemic July 21, 2011 Audience: Healthcare Professionals. ISSUE: FDA notified healthcare professionals that it is reviewing data from a clinical trial that evaluated the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial fibrillation. The study was stopped early after the data monitoring committee found a two-fold increase in death, as well as two-fold increases in stroke and hospitalization for heart failure in patients receiving Multaq compared to patients taking a placebo. FDA is evaluating whether and how the preliminary results of the PALLAS study apply to patients taking Multaq for paroxysmal or persistent atrial fibrillation or atrial flutter. The PALLAS study results are considered preliminary at this time because the data have not undergone quality assurance procedures and have not been completely adjudicated. FDA will update the public when more information is available.  |
| Copyright © 2011 Drugs.com. All rights reserved. Change your notification settings or unsubscribe here. |
